Compare Ryanair Holdings plc (RYAAY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs State Street SPDR S&P Biotech ETF — how do they compare? Ryanair Holdings plc trades at $54.25 (market cap $27.24B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Ryanair Holdings plc pays a 1.66% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ryanair Holdings plc nearer its low. Which is the better fit depends on your goals.
| RYAAY | XBI | |
|---|---|---|
Market Cap | $27.24B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $73.82 | $169.55 |
52-Week Low | $53.24 | $93.43 |
Enterprise Value | $24.19B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.37, down 1.79% today, with bearish technical signals but strong fundamentals including 12.13% net margins and 22.41% ROE. Recent earnings show mixed results with a Q1 beat but Q2 miss, while Q3 expectations are high at $3.38 EPS. The company maintains robust cash flow from operations at $3.42B despite net cash flow turning negative in 2025. Analyst consensus remains positive with 62.5% buy ratings, though recent news highlights concerns about oil price exposure and reduced traffic forecasts.
The outlook balances strong profitability and market position against near-term headwinds from fuel costs and competitive pricing. Investment opportunity lies in Ryanair's industry-leading efficiency and potential market share gains during industry consolidation. Key risks include unhedged fuel costs, winter capacity cuts, and macroeconomic sensitivity. The stock's current valuation at 13.04 P/E appears reasonable if the company can maintain its earnings trajectory amid industry challenges.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
